.Kaufmann, P., Pariser, A. R. & Austin, C. From medical discovery to procedures for uncommon diseasesu00e2 $" the scenery from the National Center for Progressing Translational Sciencesu00e2 $" Workplace of Rare Diseases Study. Orphanet J. Rare Dis. 13, 196 (2018 ). Articleu00c2.PubMedu00c2.Google.com Scholaru00c2.Crooke, S. T. A phone call to upper arms against ultra-rare conditions. Nat. Biotechnol. 39, 671u00e2 $ "677 (2021 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Vockley, J. et al. The growing role of clinical geneticists in the era of genetics therapy: a necessity to prepare. Genet. Medication. 25, 100022 (2023 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Kim, J. et al. Patient-customized oligonucleotide therapy for an uncommon hereditary disease. N. Engl. J. Med. 381, 1644u00e2 $ "1652 (2019 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Kim, J. et al. A structure for tailored splice-switching oligonucleotide treatment. Nature 619, 828u00e2 $ "836 (2023 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Lima, W. F. et al. Individual RNase H1 discriminates between subtle variations in the construct of the heteroduplex substratum. Mol. Pharmacol. 71, 83u00e2 $ "91 (2007 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Crooke, S. T., Cook, B. F., Crooke, R. M. & Liang, X.-H. Antisense technology: a guide and also prospectus. Nat. Rev. Medication Discov. 20, 427u00e2 $ "453 (2021 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Lee, J.-R. et cetera. De novo mutations in the motor domain of KIF1A cause cognitive impairment, spastic paraparesis, axonal neuropathy, and cerebellar atrophy. Hum. Mutat. 36, 69u00e2 $ "78 (2015 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Boyle, L. et cetera. Genotype and defects in microtubule-based mobility connect along with medical severeness in KIF1A-associated neurological condition. HGG Adv. 2, 100026 (2021 ). CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Kondo, M., Takei, Y. & Hirokawa, N. Electric motor healthy protein KIF1A is actually important for hippocampal synaptogenesis as well as finding out enhancement in a developed setting. Nerve cell 73, 743u00e2 $ "757 (2012 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Guo, Y. et al. An unusual KIF1A missense anomaly boosts synaptic functionality and boosts confiscation activity. Front end. Genet. 11, 61 (2020 ). Articleu00c2.CASu00c2.PubMedu00c2.PubMed Centralu00c2.Google Scholaru00c2.Kaur, S. et al. Development of the phenotypic range of afresh missense alternatives in kinesin member of the family 1A (KIF1A). Hum. Mutat. 41, 1761u00e2 $ "1774 (2020 ). Articleu00c2.CASu00c2.PubMedu00c2.PubMed Centralu00c2.Google Scholaru00c2.Canivez, G. L. & McGill, R. J. Aspect structure of the Differential Potential Scales-Second Version: exploratory and hierarchical factor studies along with the primary subtests. Psychol. Evaluate. 28, 1475u00e2 $ "1488 (2016 ). Articleu00c2.PubMedu00c2.Google Scholaru00c2.Epstein, A. et al. Content recognition of the quality of life inventoryu00e2 $" handicap. Childcare Wellness Dev. Forty five, 654u00e2 $ "659 (2019 ). Articleu00c2.PubMedu00c2.Google.com Scholaru00c2.Lek, M. et al. Analysis of protein-coding genetic variety in 60,706 people. Nature 536, 285u00e2 $ "291 (2016 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.IND Submissions for Individualized Antisense Oligonucleotide Medication Products for Drastically Incapacitating or Life-Threatening Conditions: Professional Recommendations (United States Food and Drug Administration, 2022) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or-lifeIND Articles for Individualized Antisense Oligonucleotide Drug Products: Managerial and Procedural Referrals Guidance for Sponsor-Investigators (US Fda, 2021) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-administrative-and-proceduralInvestigational New Medication Request Entries for Tailored Antisense Oligonucleotide Medicine Products for Badly Debilitating or Serious Conditions: Chemical Make Up, Manufacturing, and also Controls Recommendations, Direction for Sponsor-Investigators (US Fda, 2022) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-new-drug-application-submissions-individualized-antisense-oligonucleotide-drugNonclinical Testing of Individualized Antisense Oligonucleotide Medicine Products for Drastically Debilitating or even Severe Diseases Support for Sponsor-Investigators (US Food and Drug Administration, 2021) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-testing-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or.